The new idea for controlled release PRP therapy in women hair-loss
Recently, Platelet Rich Plasma (PRP) topical injection therapy is reported to be efficient for women hair loss but its effect is still not enough. And also the patients may fall into anemia because of repeated drawing blood. The mechanism of PRP is to provide growth factors around the cell and up-regulate cell function so they have to continue signaling to maintain cell function. Therefore concept of controlled release carrier is focused by engineers and researchers all over the world and they have developed many kinds of drag carriers but are still expensive or under research so they are not suit for clinical use. Takikawa et al reported new cheap carrier containing PRP using conventional injectable drugs. They use Dalteparin and protamine micro-particles (D/P MPs) as the carrier for PRP and investigate the duration and the enhanced effects of PRP. It can be make easily with common technique and materials in the clinic operation room. Author reports the small clinical experiences of Controlled Release PRP therapy for women hair-loss. Further investigation and improvement will be needed but the result supports the efficacy of the controlled release PRP therapy. It can be useful for not only hair growth but also rejuvenation skin therapy.
Minoru Arakaki has completed his PhD from Nagasaki University and Post-doctoral studies from Nagasaki University School of Medicine. He is currently the President of Arakaki Plastic Surgery. He is a certified board of JPRS and a counselor of JSAPS. He has published more than 20 papers in reputed journals. He is the specialist of Hair Restoration Therapy in Japan.
Androgenic alopecia (AGA) and alopecia areata (AA) are common hair loss disorders affecting adult populations worldwide. Alopecia areata is an autoimmune cause of hair loss and most common type in younger populations. Androgenic alopecia, also known as male pattern hair loss (MPHL) is the most common form of alopecia and affects up to 80% of white men and 40% of women. 1 With such a strong prevalence, Physician Assistants in any field, certainly dermatology, can expect to council patents on alopecia throughout their careers. The etiology of male pattern hair loss is androgen-dependent, and a genetically determined trait. Dihydroxytestosterone (DHT) synthesized from testosterone by an enzyme called 5apha-reductase is thought to be the principal agent for MPHL
